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Abstract 
 The INK4b-ARF-INK4a locus encodes two members of the INK4 family of cyclin-
dependent kinase inhibitors, p15INK4b and p16INK4a, and a completely unrelated protein called 
ARF. ARF is a nucleolar protein with unusual structure that exhibits tumor suppressive 
functions. There is growing evidence that ARF signaling is complex, and involves p53-
dependent or p53-independent pathways aiming mainly at restrain abnormal cell growth and 
at maintain genomic stability. As such, ARF is a critical component of tumor surveillance, 
and its expression is decreased in human tumors. In this review, we present the current 
knowledge on ARF regulation and major functions. The ARF status in human tumors is also 
briefly summarized. 
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 ARF (known as p14ARF in human and p19ARF in mouse) was originally identified as an 
alternative transcript of the INK4b-ARF-INK4a locus located on human chromosome 9p21 1. 
This locus encodes two members of the INK4 family of cyclin-dependent kinase inhibitors, 
p15INK4b and p16INK4a, that regulate progression through the G1 phase of the cell cycle. The 
intercalation of an additional exon (called exon 1 beta) between INK4b and INK4a renders 
the simple tandem arrangement more complex, as its transcription by a distinct promoter 
produces a transcript that also incorporates exons 2 and 3 of INK4a. However, because exon 2 
of ARF is translated in an alternative reading frame (ARF) to that used for INK4a, the ARF 
product is unrelated to the INK4a protein. As a consequence, p16INK4a and ARF are not 
isoforms, do not share any amino acid homology and have distinct functions in the cells. 
Nevertheless, like p16INKA4, ARF exhibits tumor suppressive functions as demonstrated by the 
tumor susceptibility phenotype of ARF/INK4a-deficient mice (Table 1). Indeed, mice that are 
defective for any one of the genes have increased susceptibility to spontaneous or carcinogen-
induced tumors, albeit to different degrees 2, 3. Arf-null mice develop tumors early in life 
whereas p16INK4a-null mice do not show predisposition to spontaneous tumor within 17 
months 4. Furthermore, the phenotype resulting from disruption of both p16INK4a and p19ARF is 
comparable to that produced by disruption of p19ARF alone 2, 5. Although these results suggest 
a predominant role of p19ARF over p16INK4a, each product acts in a non-redundant manner to 
significantly contribute to tumorigenesis « in vivo » and the effects are excerbated in animals 
that lack both genes. Studies of mouse embryo fibroblasts (MEFs) derived from the knockout 
strains also emphasize the independent role of ARF. In wild type MEFs, both p19ARF and 
p16INK4a accumulate significantly after passaging. However, spontaneous escape from 
senescence occurs through loss of the ARF-p53 axis rather than INK4a-Rb. In addition, ARF-
null MEFs expressing functional p16INK4a fail to undergo crisis after multiple passages « in 
vitro » and are efficiently transformed by oncogenic Ha-ras 2. In contrast, p16INK4a-null MEFs 
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display a phenotype similar to wild-type MEFs and are not sensitive to Ha-ras transformation 
3, 6
. Although these observations in MEFs do not apply to all cell types, they highlight ARF as 
a bona fide tumor suppressor « per se », independent from p16INK4a. 
 
ARF is a peculiar protein with unusual primary structure 
 The primary structure of ARF is puzzling. The mouse protein is predicted to be 169 
amino acids and the human protein only 132 amino acids. Both proteins share only limited 
sequence homology (50%) that could explain some of their functional differences. 
Nevertheless, they are both composed of more than 20% arginine residues confering them 
highly basic and hydrophobic properties. Interestingly, there are no recognizable structural 
motifs in ARF proteins and the protein probably needs to form complexes with other 
molecules, both to be folded and for its charge to be neutralized at physiological pH. This 
probably explain the increasing number of yet identified ARF partners 7. Mouse p19ARF 
contains only one lysine and human p14ARF has none. Mouse p19ARF and human p14ARF 
contain only single internal methionine residues (Met45 and Met48 respectively) which is 
absent in other species (rat, opossum, pig and chicken). Translational initiation from these 
methionine residues produces both in mouse and human a short form of the protein that, when 
overexpressed, localizes to mitochondria (smARF) 8. Nevertheless, full-length ARF 
preferentially localizes in the nucleoli thanks to nucleolar localization signals (NoLS). p19ARF 
contains a unique NoLS in its exon1β (aa 26-37) which deletion induces the nuclear 
translocation of the protein 9. The situation is more complex for p14ARF as two NoLS have 
been identified in the protein. The first one localized in exon1β plays a key role in the 
antiproliferative function of p14ARF as its deletion inhibits the ability of p14ARF to stop the cell 
cycle and to bind Mdm2 10. The second one stands in exon 2 (aa83-101) and is involved in the 
ability of p14ARF to promote the sumoylation of its binding partners 11.  
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ARF expression and turnover 
 P19ARF expression is very low during embryogenesis except in a subset of perivascular 
cells in the eyes of developping mouse embryos, in which upregulation of p19ARF blocks 
proliferation driven by PDGFβ to promote hyaloid vascular regression 12. Induction of p19ARF 
expression has been recently ascribed to ΤGFβ2 control in that way 13. Expression of p19ARF 
is also increased in senescent mouse fibroblasts 14. The situation is less clear for p14ARF as its 
expression level remains low as cells near senescence 14 and p14ARF depleted cells still 
undergo a senescence-like arrest when challenged with Ras. However, p14ARF seems to be an 
important mediator of the senescent phenotype induced by E2F1 suggesting that p14ARF could 
play a role in some types of oncogene-induced senescence 15. Ectopic expression of a variety 
of oncogenes such as Ras, c-myc, E1A, and E2F1 upregulates p19ARF expression as part of a 
checkpoint response that limits cell cycle progression in response to hyperproliferative signals 
16
. The regulation of p14ARF is less known and its responsiveness is distinct from that of 
p19ARF as E2F1 induces the transcription of p14ARF whereas Ras or c-myc do not. P14ARF 
expression is also increased after exposure to some radiations and genotoxic drugs, and 
contributes to the DNA damage response that eliminates damaged cells from the proliferative 
pool 7. It has also been shown that ARF expression is induced by viral infection and acts to 
reduce viral infectivity 17. Together, these data place ARF as a general sensor of different 
types of cellular stress. The mechanisms involved in ARF regulation are largely unknown but 
recent data give some clues as to how ARF expression might be regulated in response to 
specific stresses. As an example, it has been demonstrated that in a context of oncogene- and 
stress-induced senescence, the histone H3 Lysine 27 demethylase JMJD3 can overcome 
INK4a/ARF silencing imposed by the polycomb group (PcG), by removal of H3K27me3 
from the INK4a/ARF promoters 18. In addition, transcription-independent mechanisms of 
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ARF regulation that involve ubiquitination and degradation of ARF have been reported during 
responses to oncogenic stress such as c-myc 19. 
 The mechanisms that regulate ARF turnover is still not yet completely clear although 
two residues in exon1β were recently found to be essential for p14ARF stability 20. Both mouse 
and human ARF are relatively stable proteins with estimated half-life ranging from 
approximately 1-8h. Some studies have shown that ARF degradation depends, at least in part, 
on the proteasome and that, although it lacks lysine, ARF can undergo N-Terminal 
ubiquitination independently of p53 and MDM2 21. Recently, a specific ubiquitin ligase for 
ARF called ULF was identified 19. Interestingly, oncogenic stress such as c-Myc abrogates 
ULF-mediated ARF ubiquitylation and promotes ARF-dependent, p53-mediated growth 
arrest. On the other hand, an « in vitro » degradation of ARF by the 20S proteasome in the 
absence of ubiquitination has also been reported, a process counteracted by TBP1, a 
component of the regulatory subunit of the proteasome 21. While it remains unclear how ARF 
could be adressed to the proteasome in the absence of ubiquitination, recent data have reveal 
that the REG-γ proteasome could be involved in the ubiquitin-independent regulation of ARF 
turnover 21. Studies on subcellular localization of ARF also give some clues about its stability. 
ARF is stable when expressed within the nucleolus, but turns over more rapidly in the 
nucleoplasm. In the nucleolus, the ARF protein assumes a stable structure thanks to its 
sequestration by nucleophosmin (NPM/B23) that prevents its nucleoplasmic degradation 22, 23. 
Therefore, NPM is responsible not only for protecting ARF from degradation, but also for its 
nucleolar compartmentalization.  
 
Biological functions of ARF 
 The ARF response is quite complex. Although it was first assessed that the chief 
function of ARF was to suppress aberrant cell growth by inducing the p53 pathway which 
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mediates tumor suppression, there is now ample evidences that ARF also displays p53-
independent activities. These p53-independent functions are heterogeneous and although 
several potential regulators have been identified, the molecular basis of p53-independent ARF 
signaling remains largely unelucidated. Here, we briefly review the major functions of ARF 
(Table 2).  
The role of ARF in tumor suppression 
ARF is a key activator of the p53 pathway 
 One of the most well-defined function of ARF is to suppress aberrant cell growth in 
response to oncogene activation, by activating the transcription factor p53 that triggers the 
expression of many apoptosis inducers and cell cycle inhibitory genes 16. ARF is thought to 
stabilize and stimulate p53 activity by neutralizing the inhibitory effects of two ubiquitin 
ligases, Mdm2 and ARF-BP1/Mule (ARF-binding protein1/Mcl1-ubiquitin ligase E3) (Fig 1). 
Both proteins are specific ubiquitin ligase for p53 and can inhibit its tumor suppressor 
functions. Overexpressed ARF interacts directly with Mdm2 and blocks Mdm2-mediated 
ubiquitination, nuclear export and degradation of p53 by the proteasome 7. ARF can also 
relocalizes MDM2 to nucleoli thus blocking ubiquitination and nuclear export of p53. Other 
studies show that ARF promotes p53 stabilization and cell cycle arrest without relocalization 
of endogenous Mdm2 to nucleoli 24 25. Beside, ARF can also stimulate the p53 pathway by 
targeting the ARF-BP1 ubiquitin ligase. Following aberrant oncogene activation, ARF is 
induced and inhibits the proteasomal degradation of nuclear p53 by ARF-BP1, thereby 
promoting p53-dependent cell cycle arrest or apoptosis 26.  
 
ARF displays inhibitory cell growth control independently of p53 
 If ARF is undoubtedly a critical component of the p53 pathway, there is now evidence 
that ARF has also the ability to restrain cell growth independently of p53. Overexpression of 
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p19ARF can induce a G1 arrest in cells lacking p53 27, 28. Human p14ARF can stop the cells in S 
phase and/or trigger apoptosis by mechanisms that do not require the expression of a wild 
type p53 protein 29 30. We have also demonstrated that p14ARF inhibits the growth of human 
lung tumor cells lacking p53 by inducing a G2 arrest followed by apoptosis both in “in vitro” 
and “in vivo” models . In this last case, enforced p14ARF expression prevents tumor growth 
and induces the regression of lung tumors established in nude mice 31-33. Moreover, several 
groups of investigators have shown that ARF interacts with and antagonizes the 
transcriptional function of Myc and E2F1 independently of p53, both proteins being potent 
oncogenes required for cell cycle progression 7. ARF does not interfere directly with the 
DNA-binding of these transcription factors on their target promoters, but induces their 
nucleolar sequestration and/or prevents the recruitment of coactivators. As both Myc and 
E2F1 stimulate ARF expression, these results highlight p53-independent negative feed-back 
mechanisms. All these studies are consistent with the findings that mice lacking ARF, p53 
and Mdm2 are more tumor prone than those lacking only p53 and Mdm2, and that ARF-/- and 
+/- mice develop a broader spectrum of tumors than p53-null animals 4, 28. They support a role 
of ARF in mediating p53-independent tumor suppressive functions, and suggest that ARF 
also acts independently of the Mdm2-p53 axis in tumor surv illance. 
 
ARF attenuates ribosomal RNA transcription and processing 
 ARF predominantly resides within the nucleolus where it can bind to NPM 34, 35. NPM 
is an abundant nucleolar protein which expression level correlates directly with the 
proliferative state of a cell. NPM is involved in diverse cellular processes including ribosome 
biogenesis 36. In response to oncogenic stress, ARF enters the nucleolus to form stable 
complexes with NPM. The biological consequences of the ARF-NPM complex is a subject of 
debate 7. The prevailing view is that ARF exerts its growth inhibitory activities within the 
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nucleolus. Indeed, ARF retards rRNA transcription and processing, interferes with NPM 
nucleocytoplasmic shuttling, and impedes ribosome export from the nucleus to the cytoplasm. 
On the other hand, it has been suggested that sequestration by NPM in the nucleolus could 
hold ARF inactive towards growth suppression, and that its nucleoplasmic translocation 
promotes p53 interaction and cell cycle arrest notably through Mdm2 inhibition. Interestingly, 
as same domains of ARF mediate nucleolar localization and Mdm2 binding, it has been 
suggested that Mdm2 and NPM could compete for ARF association. Therefore, ARF may use 
ribosome function to inhibit cell growth through binding with NPM in the nucleolus, and may 
also regulate the p53 pathway through its interaction with Mdm2 and ARF-BP1 in the 
nucleoplasm. 
 
ARF contributes to the DNA damage response 
 Several studies have underscored a role of ARF in the DNA damage response. ARF-
null mice exposed to ionizing radiations develop more frequently tumors than do wild-type 
mice 4. Furthermore, ARF enhances DNA-damage-induced apoptosis 37 and is required for 
some forms of DNA damage response 38. The p53 pathway is activated during the DNA 
damage response and the induction of p53 is coordinated by the ataxia-telangiectasia mutated 
(ATM) and ataxia-telangiectasia and Rad3-related (ATR) protein kinases which mediate the 
rapid destruction of Mdm2. In irradiated ARF-/- MEFs, sustained induction of p53 requires 
the expression of p19ARF 38 and the UV sensitization effect of ectopic ARF is dependent on 
p53 coexpression 39. Other studies have demonstrated that ARF is a component of the p53 
response following ionizing radiation, UV exposure and genotoxic treatment 40. Therefore, 
there is good evidence that ARF contributes to the p53 response following DNA damage. 
Nevertheless, some studies also point to the fact that ARF could influence the activity of 
ATM/ATR kinases by mechanims that do not involve the p53-Mdm2 axis. Enforced 
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expression of p14ARF has been reported to trigger ATR/CHK1-dependent NFkappaB 
phosphorylation leading to the inhibition of the transactivating activity of NFkappaB and to 
further TNFα-dependent apoptosis 41. Moreover, we have demonstrated that p14ARF activates 
ATM/ATR/CHK signaling pathways in response to various genotoxic drugs and induces p53-
independent cell cycle arrest and apoptosis 42. Activation of ATM/CHK2 signaling cascade is 
triggered by a p14ARF-mediated stabilization of the Tip60 protein, an histone acetyltransferase 
that activates ATM through acetylation 43. Therefore, these results situate ARF as an upstream 
regulator of the ATM/ATR signaling pathways and suggest that ARF might act as a sensor of 
damaged cells. Consistent with this hypothesis, we and others have demonstrated that UV and 
genotoxic agents stimulate p14ARF expression in cultured cells 7. Very recently, a p53-
independent role of ARF in the regulation of XPC expression after UV irradiation that is 
independent of p53 has been described, implicating ARF in nucleotide excision repair (NER) 
44
. Moreover, p14ARF has also been reported to control chromosomal stability in p53-null 
cells, and three key residues that reside outside the established functional domains of p14ARF 
have been identified as critical for maintaining and/or promoting chromosomal stability 20. 
Collectively, these studies support the idea that ARF stimulates pathways that are significant 
in maintaining genomic integrity and plays a role in genome stability (Fig 2). 
 
Other ARF functions 
ARF promotes autophagy 
 Translational initiation from internal methionine residue produces a short 
mitochondrial form of ARF (smARF) in both mouse and human 8. If smARF is rapidly 
degraded by the proteasome under physiological conditions, it accumulates in mitochondria in 
response to abnormal proliferative signals. smARF alters the mitochondrial membrane 
potential and triggers type II caspase-independent autophagic cell death, a process usually 
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initiated in response to nutrient starvation in which cells digest their own organelles to drive 
energy. Depending on the cellular context, this cell death is dependent or independent of p53 
and Bcl-2 8. More recently, full-length ARF was also reported to trigger autophagy in both 
p53-dependent and p53-independent manners, suggesting that autophagy is another effector 
of ARF functions 45.  
 
ARF induces the sumoylation of its binding partners 
 Enforced expression of ARF promotes the sumoylation of lysine residue of the 
proteins to which it binds, including Mdm2 and NPM 46. Sumoylation is a process analogous 
to ubiquitination in which a SUMO (Small Ubiquitin-like Protein) motif is covalently added 
to a target protein by using sequentially the activating (E1), conjugating (E2) and ligase (E3) 
enzyme cascade. The mechanism of ARF-induced sumoylation is unknown. ARF does not 
seem to control the activity of SUMO proteases required to cleave SUMO proteins before 
conjugation 47. However, its ability to associate with UBC9 (E2) 48 indicates that it might 
facilitate the transfert of SUMO from the E2 complex to ARF-binding proteins. The 
biological impact of ARF-mediated sumoylation is unknown. Effects of sumoylation are 
diverse and can control protein trafficking and stability, ubiquitination, transcription factors 
activities, DNA repair and centromeric cohesion. Therefore, it has been suggested that 
sumoylation could contribute to the various p53-independent functions of ARF 46. 
 
Deregulation of p14ARF in tumors  
 Considering that the INK4a/ARF locus encodes tumor suppressor genes that play a 
pivotal role in the control of the RB/p53 network, genetic abnormalities that target this locus 
are common events in human cancers. However, because of the unusual structure of the locus, 
inactivation of the ARF gene is often accompagnied by inactivation of the INK4a gene. 
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Indeed, homozygous deletions of the INK4a/ARF locus is a frequent event in tumors and 
mutations in exon 2 that affect both p16INK4a and p14ARF proteins are also observed although 
to a lesser extend 16. Because the incidence of genetic alterations that specifically inactivate 
p14ARF but not p16INK4a is still a subject of debate, the pathogenic and biological significance 
of p14ARF gene alterations in human cancers is still unclear. Furthermore, although ARF null-
mice develop spontaneous tumors at an early age, germ-line mutations affecting specifically 
exon l beta have not been yet identified, and mutations that specifically target exon1beta are 
rare in human tumors.  
 Because the physiological level of p14ARF is very low and the commercial p14ARF 
antibodies hard to work by immunohistochemistry, expression of p14ARF has been mainly 
studied at the mRNA level in human tumors (Table 3). The promoter region of p14ARF 
possesses CpG islands that can be methylated and control specifically p14ARF expression 
without affecting p16INK4a expression 49. Methylation of the p14ARF promoter has been 
reported, although at various frequencies, in different tumor samples such as colorectal 50, 
gastric 51 and prostate carcinomas 52. In breast cancer, homozygous deletion, loss of 
heterozygosity and promoter hypermethylation could explain most of the decrease of p14ARF 
mRNA 53. Moreover, one of the most frequent chromosomal translocation t(8;21) of acute 
leukaemia creates a fusion protein named AML1-ETO that specifically represses the 
transcription of p14ARF 54. We previously performed a comprehensive analysis of p14ARF 
status in lung tumors of all histological types and observed a loss of p14ARF protein, more 
frequently in small cell lung cancer (SCLC) than in non small cell lung cancer (NSCLC) 55. 
No deleterious mutation was found in exon 1beta and 2, and a beta transcript was still 
expressed in the majority of NSCLC having lost the protein suggesting a yet non identified 
mechanism of inactivation. Further studies have confirmed the aberrant pattern of p14ARF 
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expression in NSCLC 56, 57. However, although hypermethylation of p14ARF promoter was 
reported in some studies 56, 58, this was not found in other ones 59. 
 Deregulation of proteins that affect p14ARF expression might be an alternative way to 
explain its aberrant status in tumors. For example, overexpression of the Bmi-1 repressor 
correlates with inhibition of both p16INK4a and p14ARF proteins in colon cancer 60 and 
Pokemon and p14ARF expression are negatively associated in lung tumors and cell lines 61. 
Moreover, an aberrant expression pattern of other p14ARF regulators such as TBX3, TBX2 and 
DMP1 has been reported in human tumors. However, further studies are required to analyze 
whether these proteins associate or not with deregulated p14ARF expression. More 
interestingly, recent data demonstrate that the H3K27me3 demethylase JMJD3 contributes to 
the activation of the INK4a-ARF locus 18. JMJD3 is located on chromosome 17 in close 
vicinity to the p53 gene. Therefore, allele loss at chromosome 17, which is a frequent event in 
tumors such as lung, might be an alternative way to inactivate p14ARF.  
Aberrant methylation of both p16INK4a and p14ARF promoters correlates with lymph node 
metastasis and higher tumor grade in colon cancer 62 and with a poor prognosis in breast, 
colon and bladder carcinomas 63. P14ARF methylation is associated with lower recurrence rate 
in oral cancer patients with a good clinical outcome 64. Expression of p14ARF is an 
independent predictor of both relapse and survival in squamous cell carcinoma of the anterior 
tongue 65. In hepatocellular carcinoma, increased expression of p14ARF mRNA is associated 
with a poorly differentiated phenotype 66. We did not find correlation between p14ARF protein 
expression and tumor grade or prognosis in NSCLC. However, we observed that expression 
of p14ARF and activated phospho-CHK2(Thr68), a critical determinant of the DNA damage 
response, are directly associated 42. In keeping with our demonstration on cell lines that 
p14ARF is a key component for the initiation of the ATM/CHK2 DNA damage signaling 
cascade, our results indicate that p14ARF is a critical determinant of CHK2 activation in 
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human lung tumors and suggest that its loss in lung tumors could allow tumor cells to dodge 
the CHK2 checkpoint control, thus favoring genetic instability and lung tumorigenesis. 
 
Concluding remarks 
 Because of its peculiar structure and localization within the INK4b-ARF-INK4a locus, 
dissecting the role of ARF as a “bona fide” tumor suppressor has been the focus of intensive 
studies. It is now clear that both human and mouse proteins function as important sensors of 
hyperproliferative stimuli, acting to restrict cell growth and tumor progression through both 
p53-dependent and –independent pathways. However, the ARF response is quite complex and 
the growing number of yet identified ARF partners warrants further investigations to consider 
their biological relevance in ARF signaling. As a critical component of tumor surveillance, 
ARF accumulates in response to oncogenic and genotoxic stresses and activates DNA damage 
pathways to halt cell cycle division and/or eliminate cells that have sustained irreparable 
damage. Emerging data now enlarge this point of view and suggest that ARF may counteract 
DNA damage in a way much more complex than initially thought, making this protein a 
critical sensor of genomic instability. 
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Figures legends 
Figure 1: Control of the p53 pathway by ARF 
Hyperproliferative signals generated by oncogene activation induce the accumulation of ARF. 
In turn, ARF stabilizes p53 and stimulates its transcriptional activity by inhibiting the 
negative regulation imposed by the ubiquitin ligases MDM2 and ARF-BP1/Mule, thereby 
inducing cell cycle arrest or apoptosis. The mechanism by which ARF controls MDM2 
activity toward p53 is multifaceted, depending on the activated signals and on tissue type.  
 
Figure 2: A model for the role of ARF in tumor suppression. Abnormal oncogenic signals, 
which nature depends on murin or human background, induce transcription-dependent or 
transcription-independent upregulation of ARF. Elevated expression of ARF counteracts the 
negative control of MDM2 on p53, leading to stabilization of p53 and activation of a p53-
dependent transcriptional programme that potentiates apoptosis or induces cell cycle arrest 
according to tissue type and activating signals. ARF also functions independently of p53 to 
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inhibit cell growth, notably by attenuating the transactivating activity of growth promoting 
genes such as E2F1 and c-myc. DNA damage caused by various cellular stresses stimulates 
the p53 pathway through activation of the ATM and/or ATR kinases depending of the nature 
of the inducing signal. These enzymes increase the transcriptional activity of p53 by 
promoting its phosphorylation by CHK kinases. The ability of ARF to inhibit MDM2 can 
modify the p53-dependent DNA damage response. Increased expression of oncogenes is 
thought to activate protective DNA damage responses during the early stages of tumor 
progression and to induce, independently of ARF, the p53 pathway. Some forms of DNA 
damage such as UV and cytotoxic drugs can directly stimulate expression of ARF which 
impinges on ATM and/or ATR signaling by mechanisms that do not involve the p53 
pathways but modify the activity of the ATM/ATR enzymes either directly or indirectly. 
Besides, there are also some evidences that ARF contributes to some DNA repair pathways 
and to chromosomal stability independently of p53. 
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Table 1. Phenotype of INK4a/ARF-deficient mice    
    
        
Genetic background Tumor susceptibility MEFs properties ref 
    
        
ARF/INK4a-/- Spontaneous tumors within 8.5 months    High proliferation rate  
disruption of exons2/3 (sarcomas, lymphomas)  Immortal 5 
 High sensitivity to carcinogens Transformed by oncogenic Ras  
        
    
INK4a-/- Spontaneous tumors within 17 months  Normal proliferation rate  
disruption of exon1α (sarcomas, lymphomas) Undergo senescence 3,6 
 High sensitivity to carcinogens Resist transformation by Ras  
        
    
ARF-/- Spontaneous tumors within 9,5 months High proliferation rate  
disruption of exon1β  (sarcomas, lymphomas, carcinomas) Immortal 2,4 
 High sensitivity to carcinogens Transformed by oncogenic Ras  
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Table 2. Major cellular functions of ARF   
    
       
Cellular functions Mechanisms ref  
       
      
Tumor suppression     
  
    
Cell growth control     
  Activation of p53 leading to cell cycle arrest  23, 24  
  or apoptosis    
  p53-independent cell cycle arrest or apoptosis 26-28, 31, 32  
      
Ribosome biogenesis      
  
Decreased rRNA transcription and processing 33,34  
      
DNA damage response     
  Activation of p53 pathways 40, 41,42, 43,   
  Activation of ATM/ATR/CHK pathways  44, 45  
  Activation of DNA repair pathways 47  
  Maintenance of chromosomal stability 18  
      
       
Other functions     
  
    
Autophagy Alteration of the mitochondrial membrane 7, 36  
  potential    
      
Sumoylation Association with UBC9 (E2). Biological impact 37, 38, 39  
   unknown    
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Table 3. ARF status in human tumors    
     
          
Tissue type ref Mutation type/ Frequency Association with clinical 
  expression change  parameters 
     
          
Colorectal carcinoma 49 promoter methylation 28%  
Colon cancer 61 promoter methylation 50.8% lymph node metastasis 
    high tumor grade 
 62 promoter methylation 33% tumor stage 
Gastric cancer 50 promoter methylation 24% early stage of intestinal type  
     advanced stage of diffuse type  
Prostate carcinoma 51 HD 6%  
  promoter methylation 6%  
  loss of protein exp 12.5%  
Breast cancer 52 HD 4%  
  LOH 21%  
  low/undetectable mRNA 26%  
  High level mRNA 17%  
  promoter methylation 24%  
 62 promoter methylation 24% vascular invasion 
Bladder carcinomas 62 promoter methylation  56% multicentric foci, muscle invasion 
    tumor size and tumor stage 
Oral cancer 63 HD 12%  
  promoter methylation 18% lower recurrence rate 
Squamous carcinoma  64 low/undetectable prot 20% independent predictor of bad  
of the tongue    prognosis 
Hepatocellular carcinoma 65 HD 2%  
  mutation 4%  
  increased mRNA 93% poor differentiation 
Lung carcinoma     
NSCLC 54 low/undetectable prot 25%  
  low level mRNA 18%  
  mutation 4%  
 55 low/undetectable prot 34% more frequent in ADK than in SQ 
  decreased mRNA 31%  
  promoter methylation 30%  
  HD/LOH 9%/26%  
  mutation 2%  
 56 low/undetectable prot 41%  
 57 promoter methylation 8%  
SCLC 54 low/undetectable prot 73%  
          
     
HD, Homozygous deletion; LOH, Loss of heterozygosity; ADK, adenocarcinoma; SQ, squamous carcinoma 
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